Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while?
Malene Støchkel FrankDorte Schou NørøxeLotte NygårdGitte Fredberg PerssonPublished in: BMC palliative care (2018)
Our study show that a significant number of patients who received PTR died before they could achieve optimal effect of the treatment. PS and histology were significant prognostic factors favoring PS 0-1 and squamous cell carcinoma. Based on our study, we suggest that patients with PS 0-1 should be considered for fractionated PTR whereas patients with PS ≥ 2 should be considered for high dose single fraction only or supportive palliative care.